A detailed history of Redmile Group, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 3,031,009 shares of NUVB stock, worth $8.12 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares
3,031,009
Previous 3,031,009 -0.0%
Holding current value
$8.12 Million
Previous $8.85 Million 21.23%
% of portfolio
0.46%
Previous 0.58%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.29 - $4.04 $127,802 - $1.78 Million
-440,700 Reduced 12.69%
3,031,009 $6.79 Million
Q1 2022

May 16, 2022

SELL
$4.6 - $8.83 $916,779 - $1.76 Million
-199,300 Reduced 5.43%
3,471,709 $18.3 Million
Q4 2021

Feb 14, 2022

SELL
$7.75 - $10.05 $6.74 Million - $8.74 Million
-870,000 Reduced 19.16%
3,671,009 $31.2 Million
Q1 2021

May 17, 2021

BUY
$9.0 - $14.57 $40.9 Million - $66.2 Million
4,541,009 New
4,541,009 $47.5 Million

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $582M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.